Skip to main content
SpringerLink
Log in

Factor V R506Q Mutation-Leiden: An Independent Risk Factor for Venous Thrombosis but not Coronary Artery Disease

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Background: A specific point G-A transition at nucleotide position 1691 in the factor V (FV) gene, FV-Leiden, was associated with increased risk of venous thromboembolism (VTE). Insofar as the association of FV-Leiden with coronary artery disease (CAD) remains poorly defined, the aim of this study was to determine the prevalence of FV-Leiden in a sample of 68 VTE patients, 69 CAD patients, and 192 randomly selected healthy subjects.

Methods: Total genomic DNA was extracted from the peripheral blood of study subjects and was used for PCR analysis. The presence (or absence) of FV-Leiden was assessed by PCR using primers flanking the mutant site (nt 1691), followed by hybridization with wild-type (‘G’) and mutant (‘A’) biotinylated DNA probes; detection was by DNA enzyme immunoassay (DEIA).

Results: While the prevalence of FV-Leiden in CAD patients was not statistically different from that of healthy subjects (14.5%% vs. 15.1%%; P=0.890, odds ratio 0.95; 95%% confidence interval 0.43–2.06), a significant increase in FV-Leiden prevalence was seen in VTE patients (70.6%% in VTE patients; P<0.001, odds ratio 13.4, 95%% confidence interval 6.9–25.8). Of the 48 VTE patients who tested positive for FV-Leiden, 42 were heterozygotes (G/A), while 6 were homozygotes (A/A) (allele frequency 0.397). All 10 CAD patients positive for FV-Leiden were heterozygote carriers (allele frequency 0.072). While gender was not a factor in FV-Leiden expression, higher prevalence in FV-Leiden was seen in younger (≤45 years) VTE patients (38/51 vs. 10/17).

Conclusion: FV-Leiden is a major inherited risk factor for VTE, with a peak incidence in younger patients, but does not appear to play any role in CAD pathogenesis in the population studied.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor Va by activated protein C. J Biol Chem 1994;269:31,869–880.

    Google Scholar 

  2. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.

    Google Scholar 

  3. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor V R506Q*. J Biol Chem 1995;270:4053–4057.

    Google Scholar 

  4. Dahlback B. Resistance to activated protein C as risk factor for thrombosis: Molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997;34:217–234.

    Google Scholar 

  5. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993;72:477–481.

    Google Scholar 

  6. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133–1134.

    Google Scholar 

  7. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305–1307.

    Google Scholar 

  8. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000;65:45–49.

    Google Scholar 

  9. Abdulkadir J, Feleke Y, Berg JP, Falch JA, Odegaard OR. Absence of the factor V Leiden mutation in Ethiopians. Thromb Res 1997;86:181–182.

    Google Scholar 

  10. Kim TW, Kim WK, Lee JH, et al. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep venous thrombosis. J Korean Med Sci 1998;13:587–590.

    Google Scholar 

  11. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and MnII genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995;74:996–1002.

    Google Scholar 

  12. Bertina RM. Molecular risk factors for thrombosis. Thromb Hemost 1999;82:601–609.

    Google Scholar 

  13. Rosen SB, Sturk A. Activated protein C resistance — a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem 1997;35:501–516.

    Google Scholar 

  14. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998;24:367–379.

    Google Scholar 

  15. Dahlback B. Are we ready for factor V Leiden screening? Lancet 1996;347:1346–1347.

    Google Scholar 

  16. Beauchamp NJ, Daly ME, Cooper PC, Makris M, Preston FE, Peake IR. Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V Leiden. Blood 1996;88:1700–1707.

    Google Scholar 

  17. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1994;332:912–917.

    Google Scholar 

  18. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996;131:1145–1148.

    Google Scholar 

  19. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Wit I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995;345:526–527.

    Google Scholar 

  20. Holm J, Zoller B, Berntorp E, Erhardt L, Dahlback B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239:221–226.

    Google Scholar 

  21. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817–2821.

    Google Scholar 

  22. van der Bom JG, Bots ML, Haverkate F, Slagboom E, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265–269.

    Google Scholar 

  23. Redondo M, Watzke HH, Stucki B, et al. Coagulation factors II, V, VII, and X, prothrombin gene 20210G → A transition, and factor V Leiden in coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:1020–1025.

    Google Scholar 

  24. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and the risk of premature myocardial infarction. Lancet 1994;344:1709–1710.

    Google Scholar 

  25. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation. Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999;30:2547–2553.

    Google Scholar 

  26. Irani-Hakime N, Tamim H, Elias G, Finan RR, Daccache JL, Almawi WY. High prevalence of factor V mutation-Leiden in the eastern Mediterranean. Clin Chem 2000;46:134–136.

    Google Scholar 

  27. Svensson PJ, Zoller B, Mattiasson I, Dahlback B. The factor V R506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997;241:379–385.

    Google Scholar 

  28. Ludemann P, Nabavi DG, Junker R, et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis. A case-control study of 55 patients. Stroke 1998;29:2507–2510.

    Google Scholar 

  29. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 → Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399–403.

    Google Scholar 

  30. De Stefano V, Martinelli I, Mannuccio P, et al. The risk of recurrent deep venous thrombosis among heterzygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801–806.

    Google Scholar 

  31. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thrombo-embolism in patients with and without factor V Leiden. Thromb Haemost 1997;77:624–628.

    Google Scholar 

  32. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of anticoagulation. Thromb Haemost 1999;81:684–689.

    Google Scholar 

  33. Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb Haemost 1999;81:208–213.

    Google Scholar 

  34. Vargas M, Soto I, Pinto CR, et al. The prothrombin 20210A allele and factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagul Fibrinolysis 1999;10:39–41.

    Google Scholar 

  35. Prohaska W, Schmidt M, Mannebach H, Gleichmann U, Kellsiek K. The prevalence of the prothrombin 20210 G → A mutation is not increased in angiographically confirmed coronary artery disease. Thromb Haemost 1999;81:161–162.

    Google Scholar 

  36. Margaglione M, D'Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583–1587.

    Google Scholar 

  37. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167–1173.

    Google Scholar 

  38. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822–824.

    Google Scholar 

  39. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997;78:327–333.

    Google Scholar 

  40. Walker ID. Factor V Leiden: should all women be screened prior to commencing the contraceptive pill? Blood Rev 1999;13:8–13.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, St. Georges-Orthodox Hospital, Beirut, Lebanon

    Noha Irani-Hakime, Hala Tamim, Ghanem Elias & Salah Choueiry

  2. Department of Vascular Surgery, St. Georges-Orthodox Hospital, Beirut, Lebanon

    Raghid Kreidy

  3. Department of Laboratory Medicine, St. Georges-Orthodox Hospital, Beirut, Lebanon

    Jocelyn L. Daccache & Wassim Y. Almawi

Authors
  1. Noha Irani-Hakime
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hala Tamim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ghanem Elias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salah Choueiry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raghid Kreidy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jocelyn L. Daccache
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wassim Y. Almawi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Irani-Hakime, N., Tamim, H., Elias, G. et al. Factor V R506Q Mutation-Leiden: An Independent Risk Factor for Venous Thrombosis but not Coronary Artery Disease. J Thromb Thrombolysis 11, 111–116 (2001). https://doi.org/10.1023/A:1011268531377

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011268531377

Search

Navigation